Effect of benralizumab treatment on the airway microbiome in COPD
Background One-third of patients with COPD have an eosinophilic inflammatory phenotype. Benralizumab is an afucosylated humanised monoclonal antibody that targets the interleukin-5 receptor α subunit, leading to rapid and near-complete eosinophil depletion via antibody-dependent cellular cytotoxicit...
Αποθηκεύτηκε σε:
| Κύριοι συγγραφείς: | , , , , , , , |
|---|---|
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
European Respiratory Society
2025-04-01
|
| Σειρά: | ERJ Open Research |
| Διαθέσιμο Online: | http://openres.ersjournals.com/content/11/2/00802-2024.full |
| Ετικέτες: |
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|